Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash provided by (used for) operating activities
Net income (loss)	$ 110	$ 341
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal	0	6
Depreciation and amortization	274	268
Deferred and prepaid income taxes	(75)	(1)
Stock-based compensation expense	52	47
Net loss (gain) on investments and notes receivable	20	(37)
Contingent consideration net expense (benefit)	12	(6)
Inventory step-up amortization	17	8
Foreign exchange (gain) loss	9	2
Gain (Loss) on Extinguishment of Debt	194	0
Other, net	11	22
Trade accounts receivable	(66)	(117)
Inventories	(108)	(115)
Other assets	(140)	(128)
Accounts payable, accrued expenses and other liabilities	(368)	7
Cash provided by (used for) operating activities	(58)	284
Investing activities:
Purchases of property, plant and equipment and internal use software	(121)	(75)
Proceeds from sale of property, plant and equipment	8	4
Payments for acquisitions of businesses, net of cash acquired	(1,471)	(706)
Proceeds from royalty rights	19	22
Proceeds from divestiture of certain businesses and assets	5	801
Proceeds from (payments for) investments and acquisitions of certain technologies	(15)	25
Cash provided by (used for) investing activities	(1,574)	71
Financing activities:
Payment of contingent consideration previously established in purchase accounting	(20)	(11)
Payments for royalty rights	(39)	(42)
Payments on short-term borrowings	(250)	0
Net increase (decrease) in commercial paper	223	0
Payments on long-term borrowings and debt extinguishment costs	(3,184)	0
Proceeds from long-term borrowings, net of debt issuance costs	3,271	0
Cash dividends paid on preferred stock	(14)	(14)
Cash used to net share settle employee equity awards	(46)	(46)
Proceeds from issuances of common stock pursuant to employee stock compensation and purchase plans	52	18
Cash provided by (used for) financing activities	(6)	(95)
Effect of foreign exchange rates on cash	0	(3)
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents	(1,639)	258
Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period	2,168	1,995
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period	529	2,253
Supplemental Information
Stock-based compensation expense	52	47
Fair value of contingent consideration recorded in purchase accounting	0	219
Non-cash impact of transferred royalty rights	$ (19)	$ (22)